Venous Thromboembolism Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030

Venous Thromboembolismis a disease caused by clotting of blood in blood vessel which leads to restriction of blood flow within the circulatory system. Venous thromboembolism is classified into pulmonary embolism and deep vein thrombosis. Deep vein thrombosis is mainly occurred due to the clotting of the blood in the deep vein (commonly in the leg). The formed DVT clot breaks off and flows to the lungs known as pulmonary embolism which is a severe complication of deep vein thrombosis (DVT). Venous thromboembolism commonly occurs in aged persons with more than 60 years.

The symptoms associated with the venous thromboembolism include dilated blood veins in legs and chest, edema, fever, tachycardia, and dyspnea. Lower extremities are the most common site for DVT, but other locations affected include the mesenteric, upper extremities, pelvic veins, and cerebral vein. Venous Thromboembolism is treated by blood thinners, clot-busting drugs and surgery.

  Key Developments:

• In March 2017, Daiichi Sankyo, Inc. commenced a phase 3, open-label, randomized, multi-center, controlled trial to evaluate the pharmacokinetics and pharmacodynamics of edoxaban and to compare the efficacy and safety of edoxaban with standard of care anticoagulant therapy in pediatric subjects from birth to less than 18 years of age with confirmed venous thromboembolism
• In November 2015, Pfizer in collaboration with Bristol-Myers Squibb commenced a phase 4 randomized, open label, active controlled, safety and descriptive efficacy study in pediatric subjects requiring anticoagulation of apixaban for the treatment of venous thromboembolism